Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management

CNS Drugs

Volumn 29, Issue 1, 2014, Pages 41-46

  Luedecke, Daniel ^a   Schöttle, Daniel ^a   Karow, Anne ^a   Lambert, Martin ^a   Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; PALIPERIDONE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

CONTROLLED CLINICAL TRIAL (TOPIC); DELIRIUM; DRUG BLOOD LEVEL; DRUG FORMULATION; HUMAN; INJECTION SITE REACTION; MEDICATION COMPLIANCE; MENTAL PATIENT; META ANALYSIS (TOPIC); PATIENT COMPLIANCE; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); POSTINJECTION DELIRIUM SEDATION SYNDROME; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK MANAGEMENT; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; ADVERSE EFFECTS; CHEMICALLY INDUCED; DEEP SEDATION; DELAYED RELEASE FORMULATION;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DEEP SEDATION; DELAYED-ACTION PREPARATIONS; DELIRIUM; HUMANS;

EID: 84922105489     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-014-0216-9     Document Type: Review

References (43)

1. Abott C, Keith S. Antipsychotic treatment and adherence in schizophrenia. In: Haddad P, Lambert T, Lauriello J, editors. Antipsychotic long-acting injections. Oxford: Oxford University Press; 2011.
2. Davis JM, et al. Depot antipsychotic drugs: place in therapy. Drugs. 1994;47(5):741-73.
3. Dursun S. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. J Psychopharmacol. 2005;19(5 Suppl):3-4.
4. Patel MX, De Zoysa N, Baker D, et al. Antipsychotic depot medication and attitudes of community psychiatric nurses. J Psychiatr Ment Health Nurs. 2005;12(2):237-44.
5. Kane JM, Aguglia E, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8(1):55-66.
6. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92.
7. West JC, Marcus SC, Wilk J, et al. Use of depot antipsychotic medications for medication nonadherence in schizophrenia. Schizophr Bull. 2008;34(5):995-1001.
8. Kishimoto T, Agarwal V, Kishi T, et al. Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry. 2013;18(1):53-66.
9. Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs. 2009;23(8):649-59.
10. Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr Dis Treat. 2010;6:573-81.
11. Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs. 2010;70(17):2289-313.
12. Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr Dis Treat. 2010;6:261-7.
13. Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin Pharmacother. 2011;12(4):627-33.
14. Kane JM, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(5):617-24.
15. Mallikaarjun S, Kane JM, Bricmont P, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281-8.
16. Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry. 2008;69(5):790-9.
17. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181-9.
18. Rauch AS, Fleischhacker WW. Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective. CNS Drugs. 2013;27(8):637-52.
19. Ciudad A, Anand E, Casillas M, et al. Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses. Neuropsychiatr Dis Treat. 2013;9:1737-50.
20. Detke HC, Weiden PJ, Llorca PM, et al. Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia. J Clin Psychopharmacol. 2014;34:426-34.
21. Detke HC, McDonnell DP, Brunner E, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases. BMC Psychiatry. 2010;10:43.
22. Alphs L, Gopal S, Karcher K, et al. Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases. Curr Drug Saf. 2011;6(1):43-5.
23. Novakovic V, Adel T, Peselow E, et al. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS). Clin Neuropharmacol. 2013;36(2):59-62.
24. Duran-Sindreu SF, Grasa-Bello E, Corripio-Collado I, et al. Olanzapine long-acting post-injection syndrome: a case report and brief review [in Spanish]. Actas Esp Psiquiatr. 2013;41(1):60-2.
25. McDonnell DP, Andersen SW, Detke HC, et al. Long-term safety and tolerability of open-label olanzapine long-acting injection in the treatment of schizophrenia: 190-week interim results. Clin Med Insights Psychiatry. 2011;3:37-47.
26. Eli Lilly and Company. Olanzapine pamoate depot versus oral olanzapine on treatment outcomes in outpatients with schizophrenia [ClinicalTrials.gov identifier NCT00320489]. US National Institutes of Health, ClinicalTrials.gov. http://www.clinicaltrials.gov. Accessed 30 Mar 2013.
27. Ascher-Svanum H, Montgomery WS, McDonnell DP, et al. Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons. Int J Gen Med. 2012;5:391-8.
28. Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology. 2008;33(2):298-304.
29. FDA Drug Safety Communication. FDA is investigating two deaths following injection of long-acting antipsychotic Zyprexa Relprevv (olanzapine pamoate). 2013. Available at http://www.fda.gov/Drugs/DrugSafety/ucm356971.htm. Accessed 20 June 2013
30. Saar E, Beyer J, Gerostamoulos D, et al. The time-dependant post-mortem redistribution of antipsychotic drugs. Forensic Sci Int. 2012;222(1-3):223-7.
31. Kurtz D, Bergstrom R, McDonnell D, et al. Pharmacokinetics (PK) of multiple doses of olanzapine long-acting injection (OLAI), an intramuscular (IM) depot formulation of olanzapine (OLZ), in stabilized patients with schizophrenia. Biol Psychiatry. 2008; 63(Suppl. 1):228-235.
32. Eli Lilly and Company. FDA issues not-approvable letter for Lilly's Zyprexa® long-acting injection (LAI) for schizophrenia treatment. 28 February 2008. http://newsroom.lilly.com/ReleaseDetail.cfm?ReleaseID=296550. Accessed Aug 2008.
33. Zyprexa® Relprevv™. Full prescribing information. Indianapolis: Lilly USA, LLC; 2011 Jul 5.
34. McDonnell DP, Detke HC, Bergstrom RF, et al. Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010;10:45.
35. Gulliver A, McDonnell DP, Sorsaburu S, et al. Injection-related adverse events observed with olanzapine long-acting injection [abstract]. Int J Neuropsychopharmacol. 2008;11(Suppl. 1):152.
36. Citrome L. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. Int J Clin Pract. 2009;63(1):140-50.
37. EMA. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000890/WC500054429.pdf. Accessed 30 Mar 2014.
38. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.
39. Schottle D, Kuhnigk O, Naber D. Drug safety evaluation of olanzapine pamoate. Expert Opin Drug Saf. 2013;12(6):897-903.
40. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-51.
41. Macfadden W, Ma YW, Haskins JT, et al. A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont). 2010;7(11):23-31.
42. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psychiatry. 2013;74(6):568-75.
43. European Medicines Agency. Zypadhera: procedural steps taken and scientific information after the authorisation. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Procedural-steps-taken-and-scientific-information-after-authorisation/human/000890/WC500089567.pdf. Accessed 30 Mar 2014.